INSPECS Group Valuation
Is SPEC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SPEC?
Other financial metrics that can be useful for relative valuation.
|What is SPEC's n/a Ratio?|
Price to Sales Ratio vs Peers
How does SPEC's PS Ratio compare to its peers?
|Company||PS||Estimated Growth||Market Cap|
RUA RUA Life Sciences
ABDX Abingdon Health
SPEC INSPECS Group
Price-To-Sales vs Peers: SPEC is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (4.6x).
Price to Earnings Ratio vs Industry
How does SPEC's PE Ratio compare vs other companies in the GB Medical Equipment Industry?
Price to Sales Ratio vs Fair Ratio
What is SPEC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.5x|
|Fair PS Ratio||1.4x|
Price-To-Sales vs Fair Ratio: SPEC is good value based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).
Share Price vs Fair Value
What is the Fair Price of SPEC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SPEC (£1.02) is trading above our estimate of fair value (£1.02)
Significantly Below Fair Value: SPEC is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.